3 citations
,
March 2018 in “European Urology Supplements” Using 5-alpha-reductase inhibitors may improve bladder cancer survival in men.
2 citations
,
May 2019 in “PubMed” Oral finasteride and dutasteride may negatively affect erectile function in rats.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
September 2025 in “Journal of the American Academy of Dermatology” Some JAK inhibitors are effective for significant hair regrowth in alopecia areata.
2 citations
,
January 2023 in “Curēus” Low-dose naltrexone may help reduce redness in certain scalp conditions.
November 2025 in “Reumatismo” The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.
14 citations
,
April 2009 in “Acta Medica Scandinavica” Minoxidil helps control blood pressure but has side-effects, so it's not for everyone.
April 2022 in “Reactions Weekly” 5-Alpha reductase inhibitors help treat enlarged prostate but may cause sexual side effects.
March 2008 in “British Journal of Pharmacology” Enzymes play crucial roles in metabolism, health, and disease management.
5 citations
,
May 2022 in “Clinical & Experimental Metastasis” Minoxidil and ranolazine together can reduce the spread of certain breast cancer cells.
March 2016 in “International Journal of Infectious Diseases” Peginterferon alpha-2a effectively treats acute hepatitis C in hemodialysed patients, despite some side effects.
The document's conclusion cannot be provided because the document is not available or cannot be read.
March 2023 in “The Journal of Urology” Men with better urinary symptoms have a lower risk of death.
49 citations
,
January 2021 in “Journal of The European Academy of Dermatology and Venereology” Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.
10 citations
,
April 2000 in “Archives of Oral Biology” Minocycline may cause hair loss by increasing DHT levels, but finasteride can help counteract this effect.
42 citations
,
May 2003 in “Mini-reviews in Medicinal Chemistry” New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
7 citations
,
January 2004 in “Drugs of today” 5alpha-reductase inhibitors help treat hair loss and prostate issues but may cause sexual side effects.
January 2025 in “PROTEOMICS” Drug repositioning is a promising way to quickly develop new treatments, especially for rare diseases.
5 citations
,
April 2011 in “Bioorganic & Medicinal Chemistry Letters” New Finasteride conjugate improves prostate treatment and vital signs in rats.
98 citations
,
August 2004 in “BJU international” Medications have become the main treatment for enlarged prostate symptoms, replacing surgery and watchful waiting.
November 2017 in “Journal of Surgical Academia” Visual field defects in lupus nephritis can be caused by hypertensive retinopathy, not glaucoma or medication toxicity.
16 citations
,
March 1981 in “PubMed” Minoxidil significantly lowers blood pressure in patients with hard-to-treat hypertension, but can cause fluid retention and excessive hair growth.
November 2022 in “Journal of the Endocrine Society” Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.
January 2025 in “The Pharma Innovation” Nanospanlastic vesicles can improve glaucoma treatment by enhancing drug delivery to the eye.
24 citations
,
December 2009 in “Future Medicinal Chemistry” Using computers to analyze drugs can find new uses for them, but actual experiments are needed to confirm these uses.
11 citations
,
January 1980 in “Southern Medical Journal” Minoxidil effectively treats severe hypertension but has notable side effects.
July 2024 in “Journal of Controlled Release” Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.
June 2025 in “International Journal of Nephrology and Renovascular Disease” PLA2R1 overexpression harms kidney cells by stopping their growth cycle.